Capricor Therapeutics Stock Falls After FDA Panel Vote

Capricor Therapeutics (NASDAQ: CAPR) stock tumbled after the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted 3–9 on July 29, 2026, that available evidence does not support Deramiocel’s effectiveness in treating cardiomyopathy in Duchenne muscular dystrophy (DMD). Shareholder-rights firms launched investigations ahead of the Aug. 22, 2026 Prescription Drug User Fee Act (PDUFA) decision.

FDA Advisory Vote and Regulatory Timeline

The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) met on July 29, 2026, to review Capricor’s Biologics License Application (BLA) 125842 for Deramiocel. The committee voted 3 Yes–9 No–0 abstain that the evidence does not provide substantial proof of effectiveness for the treatment. Capricor confirmed the vote and noted the advisory recommendation is non-binding.

FDA briefing documents posted July 27, 2026, challenged the data supporting the resubmission. They stated that earlier studies HOPE-2 and HOPE-2-OLE failed to provide substantial evidence of benefit. The pivotal Phase 3 HOPE-3 trial did not meet its pre-specified primary and secondary endpoints at 12 months. The FDA criticized post-hoc statistical changes, shifts in the analysis plan, and raised concerns about possible functional unblinding due to differing adverse-event profiles. Safety signals including hypersensitivity and anaphylaxis were also flagged. The briefing concluded, "The benefit-risk assessment for deramiocel appears unfavorable in the absence of evidence of effectiveness."

This setback follows a July 2025 Complete Response Letter (CRL) in which the FDA said HOPE-2 and HOPE-2-OLE did not demonstrate substantial evidence of effectiveness. The agency later lifted the CRL and resumed review of the resubmitted BLA, which relies heavily on HOPE-3 data, setting the Aug. 22, 2026 PDUFA target action date.

Company Response and Data Dispute

In a July 27 press release, Capricor defended its statistical approach, stating its analyses followed a final statistical analysis plan (SAP version 3.0) completed before unblinding. The company disputed reliance on earlier drafts, describing SAP version 1.1 as an unsigned internal draft that became obsolete after cohort B was added. Capricor maintained that HOPE-3 showed a statistically significant benefit on the primary endpoint, Performance of the Upper Limb 2.0 (PUL 2.0), with supportive cardiac effects. The company has portrayed Deramiocel as a potential treatment for cardiomyopathy in DMD and publicly asserted in December 2025 that HOPE-3 met both primary and secondary endpoints.

Following the advisory committee vote, Capricor issued a July 30 statement emphasizing that the recommendation is non-binding and highlighting the absence of any approved cardiomyopathy therapies specifically for DMD.

Investor Investigations and Legal Risks

Legal scrutiny emerged alongside the regulatory debate. On July 29, Hagens Berman announced an investigation into whether Capricor misled investors about Deramiocel’s efficacy, inviting shareholders who suffered substantial losses to submit claims. Separately, Glancy Prongay Wolke & Rotter launched a securities-fraud investigation dated July 28, citing the FDA’s critical briefing documents. Both firms focus on potential federal securities law violations related to the company’s characterization of its Phase 3 data.

The advisory committee’s negative recommendation, combined with the FDA’s statistical and safety critiques and the opening of shareholder investigations, has increased uncertainty around the resubmitted BLA and Capricor’s regulatory and legal outlook.

"The benefit-risk assessment for deramiocel appears unfavorable in the absence of evidence of effectiveness." — FDA CTGTAC briefing document